GuidelineJCO global oncology2022
Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update.
Guideline in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Triage of HPV positivity in a high HIV prevalence setting: A prospective cohort study comparing visual triage methods and HPV genotype restriction in Botswana.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2024Trial
- Choosing Wisely recommendations in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Cervical Adenocarcinoma In Situ in Young Nulliparous Patient with Persistent ASC-US and Multiple-Type HPV Infections Without HPV 16 and 18 Types-Case Report.Diagnostics (Basel, Switzerland) · 2026Article
- Cervical Cancer Screening in Transition: Global Challenges and Local Realities.International journal of women's health · 2026Review
- Gynecologic management of cervical cancer patients undergoing immunotherapy: an up-to-date narrative review.Gynecology and pelvic medicine · 2026Review
- AI-assisted cervical cytology precancerous screening for high-risk population in resource-limited regions using a compact microscope.Nature communications · 2025Article
- Advancing equity in cervical cancer screening for sexual and gender minoritized people assigned female at birth (SGM AFAB) in the United States: recommendations from healthcare equity leaders.Reproductive health · 2025Article
- Review
- Assessing disparities in cancer resources distribution in Mexico.BMC health services research · 2025Article
- Consensus in CLL: global needs matter.Blood advances · 2025Article
- Relationship Between Health Literacy and Knowledge About Gynaecological Cancer Prevention of Women.International journal of nursing practice · 2025Article
- Article
- Prevalence and Correlates of Depression and Anxiety Among Women with HPV-Related Cervical Disease: A Hospital-Based Cross-Sectional Study in Shenzhen, China.International journal of women's health · 2025Article
- Cervical Cancer 2010-2019: An Upper Midwest Catchment of 40,000 Square Miles.Journal of lower genital tract disease · 2025Article
- Defining precancer: a grand challenge for the cancer community.Nature reviews. Cancer · 2024Review
- Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care-an international Delphi study.EClinicalMedicine · 2024Article
- Impact of postsurgical vaginal microbiome on high-risk HPV infection and recurrence risk in patients with cervical cancer and intraepithelial neoplasia: A retrospective study.Gynecologic oncology reports · 2024Article
- ASCO Global Guidelines: Methods and Opportunities.JCO global oncology · 2024Article
- Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Culturally Competent Education and Human Papillomavirus Self-Sampling Achieves Healthy People 2030 Cervical Screening Target Among Low-Income Non-Hispanic Black and Hispanic Women.JCO global oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 7 countries.
Funding
Abstract
purposeTo update resource-stratified, evidence-based recommendations on secondary prevention of cervical cancer globally.
methodsAmerican Society of Clinical Oncology convened a multidisciplinary, multinational Expert Panel to produce recommendations reflecting four resource-tiered settings. A review of existing guidelines, formal consensus-based process, and modified ADAPTE process to adapt existing guidelines was conducted. Other experts participated in formal consensus.
resultsThis guideline update reflects changes in evidence since the previous update. Five existing guidelines were identified and reviewed, and adapted recommendations form the evidence base. Cost-effectiveness analyses provided indirect evidence to inform consensus, which resulted in ≥ 75% agreement. RECOMMENDATIONS: Human papillomavirus (HPV) DNA testing is recommended in all resource settings; visual inspection with acetic acid may be used in basic settings. Recommended age ranges and frequencies vary by the following setting: maximal: age 25-65 years, every 5 years; enhanced: age 30-65 years, if two consecutive negative tests at 5-year intervals, then every 10 years; limited: age 30-49 years, every 10 years; basic: age 30-49 years, one to three times per lifetime. For basic settings, visual assessment is used to determine treatment eligibility; in other settings, genotyping with cytology or cytology alone is used to determine treatment. For basic settings, treatment is recommended if abnormal triage results are obtained; in other settings, abnormal triage results followed by colposcopy is recommended. For basic settings, treatment options are thermal ablation or loop electrosurgical excision procedure; for other settings, loop electrosurgical excision procedure or ablation is recommended; with a 12-month follow-up in all settings. Women who are HIV-positive should be screened with HPV testing after diagnosis, twice as many times per lifetime as the general population. Screening is recommended at 6 weeks postpartum in basic settings; in other settings, screening is recommended at 6 months. In basic settings without mass screening, infrastructure for HPV testing, diagnosis, and treatment should be developed.Additional information is available at www.asco.org/resource-stratified-guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.